Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHiscox Regulatory News (HSX)

Share Price Information for Hiscox (HSX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,151.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 5.00 (0.434%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,151.00
HSX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Response to Insurance Industry Test Case Judgment

15 Sep 2020 11:25

RNS Number : 0558Z
Hiscox Ltd
15 September 2020
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION. 

Hiscox Ltd response to Insurance Industry Test Case Court Judgment

 

Hamilton, Bermuda (15 September 2020) - Hiscox Ltd (LSE:HSX), the international specialist insurer, notes the judgment (the "Judgment") delivered by the High Court of England and Wales today in the UK insurance industry test case brought by the Financial Conduct Authority (the "FCA") on the contractual interpretation of business interruption wording in certain UK property insurance policies (the "Industry Test Case").

 

In order to achieve clarity for customers on the application of relevant policies, Hiscox agreed in May to assist the FCA by participating in the Industry Test Case alongside seven other insurers.

 

The Judgment comprises more than 160 pages of legal analysis by the Court addressing important points of insurance law for the industry and customers. The Judgment clarifies that fewer than one third of Hiscox's 34,000 UK business interruption policies may respond. Coverage under these policies is essentially limited to those customers who were mandatorily closed by Government orders, and then only in certain circumstances.

 

Hiscox is assessing the Judgment in detail to ascertain how the Court's conclusions should be applied to the claims and circumstances of individual Hiscox policyholders. Any issues not addressed by the Judgment will be assessed on a case-by-case basis as part of the normal insurance loss adjustment process for claims.

 

As a result of the Judgment, the Group estimates additional COVID-19 claims arising from business interruption to be less than £100 million net of reinsurance. This encompasses claims from all divisions including Hiscox Re and is a reduction of £150 million from the upper end of the Group's previously published risk scenario.

 

All parties involved now have an opportunity to apply to the Court for permission to appeal some or all of the Judgment to a higher court. The parties may also ask that any appeal proceed directly to the Supreme Court, rather than to the Court of Appeal first, in order to expedite the appeal process. It is expected that a ruling on any such application would be made in October. The outcome of any appeal could impact loss estimates.

 

Hiscox recognises these are extremely difficult times for businesses and regrets any contract dispute with customers, which is why it is committed to seeking an expedited resolution through this Industry Test Case. In line with FCA Guidance, Hiscox will communicate an update on the Industry Test Case to relevant policyholders through the appropriate channels.

 

The Group has delivered a resilient performance in the third quarter so far, as trading conditions continue to improve in every segment. In July and August, the Group grew its gross written premiums by 19% compared to the same period last year. Over this period Hiscox Retail achieved growth in both revenues and customer numbers, with premiums up 7%, including 6% for Hiscox UK. Hiscox London Market has continued to benefit from strong rate improvement in the majority of classes, growing 19% in the two-month period, and Hiscox Re & ILS experienced accelerated rate momentum and double-digit premium growth at the July renewals.

 

The Group remains focused on supporting its customers and employees through this challenging period. There is no change to any of the estimates or guidance provided in company's interim results published on 3 August. Hiscox's capital position remains strong and the Group maintains an A rating for financial strength from S&P. The Group is deploying capital for growth in an improving market and will provide a more detailed update of its performance in its trading statement scheduled for Monday 2 November.

 

Ends

Marc Wetherhill was responsible for the disclosure of this announcement for the purposes of MAR.

For further information:

Hiscox Ltd

Marc Wetherhill, Group Company Secretary, Bermuda +1 441 278 8321

Kylie O'Connor, Group Communications Director, London +44 (0)20 7448 6656 

Ryan Thompson, Investor Relations Manager, London +44 (0)20 7448 6522Brunswick

Tom Burns +44 (0)20 7404 5959

Simone Selzer +44 (0)20 7404 5959

 

Notes to editors

About the Hiscox Group

Hiscox is a global specialist insurer, headquartered in Bermuda and listed on the London Stock Exchange (LSE:HSX). Our ambition is to be a respected specialist insurer with a diverse portfolio by product and geography. We believe that building balance between catastrophe-exposed business and less volatile local specialty business gives us opportunities for profitable growth throughout the insurance cycle. 

 

The Hiscox Group employs over 3,400 people in 14 countries, and has customers worldwide. Through the retail businesses in the UK, Europe, Asia and the USA, we offer a range of specialist insurance for professionals and business customers as well as homeowners. Internationally traded, bigger ticket business and reinsurance is underwritten through Hiscox London Market and Hiscox Re & ILS.

 

Our values define our business, with a focus on people, courage, ownership and integrity. We pride ourselves on being true to our word and our award-winning claims service is testament to that. For more information, visit www.hiscoxgroup.com.

Hiscox response to COVID-19Hiscox is committed to supporting the international response to this pandemic. The Group is supporting employees around the world with flexible and remote working as well as socially distanced office working and the provision of mental health and wellbeing services. Wherever possible operations have been reorganised to deploy more employees to provide customer support. The Group has committed to stand by existing employees by retaining all current roles during this period on full pay. Hiscox is not furloughing any staff and has not accessed any UK Government support schemes.

Hiscox is working with the rest of the insurance industry, including the Association of British Insurers, to identify where it can direct financial support that will have the most impact. Through the Hiscox Foundation, the Group is also supporting vulnerable groups via donations to established charities such as the Trussell Trust and Age UK and around the world we are donating to food banks, the Red Cross and Personal Protective Equipment (PPE) funds.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RSPEAENSFADEEFA
Date   Source Headline
8th Jun 20237:00 amRNSIFRS 17 restated results 2022
1st Jun 20235:10 pmRNSTotal Voting Rights
1st Jun 202312:12 pmRNSAnnouncement of Scrip Reference Share Price
30th May 20234:05 pmRNSDirector/PDMR Shareholding
30th May 20237:00 amRNSHiscox appoints Jonathan Bloomer Chair designate
23rd May 20233:26 pmRNSTR-1:Standard form-notification major shareholding
22nd May 202312:25 pmRNSTR-1:Standard form-notification major shareholding
15th May 20231:01 pmRNSSyndicates 33 and 6104 – results and estimates
12th May 20237:01 amRNSHiscox appoints new Independent Non Exec Director
12th May 20237:00 amRNSAGM RESULTS
11th May 20235:33 pmRNSTR-1 Standard form-notification major shareholding
9th May 202312:23 pmRNSTR-1:Standard form-notification major shareholding
4th May 20237:00 amRNSQ1 2023 Trading Statement
2nd May 20235:00 pmRNSTotal Voting Rights
5th Apr 20232:19 pmRNSDirector/PDMR Shareholding
3rd Apr 20234:08 pmRNSTotal Voting Rights
24th Mar 20231:30 pmRNSNotice of 2023 AGM & 2022 Annual Report & Accounts
22nd Mar 202311:03 amRNSDirector/PDMR Shareholding
9th Mar 20233:46 pmRNSDirector/PDMR Shareholding
9th Mar 20237:00 amRNSSyndicates 33 and 6104 – results and estimates
8th Mar 20237:01 amRNSFull Year Results
8th Mar 20237:00 amRNSRobert Childs to retire from the Board as Chairman
2nd Mar 20237:00 amRNSTotal Voting Rights to 28 February 2023
1st Feb 20234:55 pmRNSTotal Voting Rights
16th Jan 20233:13 pmRNSDirector/PDMR Shareholding
13th Jan 20236:12 pmRNSAveva Group
7th Dec 20222:21 pmRNSDirector/PDMR Shareholding
1st Dec 202212:45 pmRNSTotal Voting Rights
28th Nov 20227:00 amRNSDirector PDMR Shareholding
14th Nov 202211:08 amRNSSyndicates 33 and 6104 – results and estimates
2nd Nov 20227:00 amRNSQ3 2022 Trading Statement
1st Nov 20224:19 pmRNSTotal Voting Rights
3rd Oct 20225:06 pmRNSTotal Voting Rights
26th Sep 20224:09 pmRNSDirector/PDMR Shareholding
22nd Sep 202211:00 amRNSDirector/PDMR Shareholding
15th Sep 20222:13 pmRNSApplication to be Admitted to the Official List
7th Sep 202212:04 pmRNSAnnouncement of the Scrip Reference Share price
6th Sep 20225:10 pmRNSDirector/PDMR Shareholding
1st Sep 20222:04 pmRNSTotal Voting Rights
12th Aug 20221:38 pmRNSDirector PDMR Shareholding
10th Aug 202212:29 pmRNSSyndicate Results
9th Aug 202211:05 amRNSDirector/PDMR Shareholding
3rd Aug 20227:00 amRNSInterim Report
6th Jul 202211:35 amRNSTotal Voting Rights
15th Jun 20222:05 pmRNSDirector/PDMR Shareholding
9th Jun 20221:09 pmRNSApplication to be Admitted to the Official List
31st May 20223:29 pmRNSAnnouncement of Scrip Reference Share Price
17th May 20225:30 pmRNSDirector/PDMR Shareholding
13th May 20223:30 pmRNSAppointment of Paul Cooper
13th May 20223:15 pmRNSAGM Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.